PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2023
CASE
AUTH/3821/9/23 Novo Nordisk ⭐ Case of the Week

Novo Nordisk: sponsorship of pharmacy weight-loss services, free consumables and missing Disclosure UK entry (Saxenda) | AUTH/3821/9/23

PMCPA found Novo Nordisk breached Clauses 2, 5.1/9.1 and 28.1 over pharmacy-chain sponsorships that weren’t truly arm’s length, free consumables seen as…

2023
CASE
AUTH/3834/10/23 AbbVie

AbbVie: Rinvoq webinar registration page and omission of grapefruit warning (AUTH/3834/10/23) – No breach

Complaint said a Rinvoq HCP webinar registration page gave dosing but omitted the SmPC grapefruit avoidance warning. Panel found the page wasn’t…

2023
CASE
AUTH/3789/7/23 Moderna

AUTH/3789/7/23: Complainant v Moderna β€” e-consent proposal and proactive scientific communications (No breach)

Complaint about a regional e-consent proposal and alleged proactive sharing of preprint data/off-label risk. Panel found the complainant provided limited evidence and…

2023
CASE
AUTH/3791/7/23 Moderna

AUTH/3791/7/23: Complainant v Moderna β€” whistleblowing processes and alleged off-label promotion (No breach)

Anonymous complaint alleged inadequate whistleblowing processes and potential off-label promotion via a Moderna US webcast. Panel found the complainant did not prove…

2024
CASE
AUTH/3874/02/24 Sanofi

Sanofi: LinkedIn job-title post naming three POM brands – no breach (AUTH/3874/02/24)

A Sanofi Global employee’s LinkedIn job update included three product brand names and was liked/commented on by UK staff. Panel found the…

2023
CASE
AUTH/3805/7/23 ViiV ⭐ Case of the Week

AUTH/3805/7/23: ViiV dating-app Apretude advert seen in UK – Appeal Board found out of scope, no breach

A US-only Apretude in-app advert was briefly visible to UK users after geo-restrictions failed. Panel initially found a Clause 5.1 breach, but…

2023
CASE
AUTH/3861/12/23 Novartis Pharmaceuticals UK

AUTH/3861/12/23: Novartis – third‑party β€œconference update” email and webpage found to disguise promotion and use EU (not UK) prescribing context

Third‑party publisher email implied an unbiased ESMO update but linked to a page integrating Novartis Pluvicto promotion. UK HCPs saw EU SmPC/indication,…

2024
CASE
AUTH/3900/5/24 AstraZeneca

AUTH/3900/5/24: Ex-Employee v AstraZeneca (meetings, hospitality and alleged inducement) – No breach

Ex-employee alleged excessive alcohol/hospitality and inducement to prescribe at a conference, plus a poorly attended workshop becoming a β€œpseudo advisory board”. Panel…

2024
CASE
AUTH/3916/5/24 Angelini Pharma UK-I

Angelini: off-label discussion at meetings, disparaging EMA comments, and portal slide compliance failures (Ontozry) | AUTH/3916/5/24

Ex-employee complaint about Ontozry meetings. Panel found off-label promotion (incl PEG administration and monotherapy advocacy), references to EMA, and multiple certification/PI/AE statement…

2008
CASE
AUTH/2081/1/08 Teva ⭐ Case of the Week

Teva found in breach for disguised promotion via sponsored β€œGuidelines in Practice” supplement (AUTH/2081/1/08)

A PCT pharmacist alleged a Teva-supported supplement about switching to CFC-free beclometasone inhalers was disguised promotion for Qvar. The Panel ruled Teva’s…

2008
CASE
Chemical Developments

Orphan Europe v Special Products and Chemical Developments: Internet promotion of unlicensed medicines

Two websites promoted unlicensed N-carbamyl-L-glutamic acid and anhydrous betaine powders with therapeutic indications and dosing information. The Panel ruled this amounted to…

2008
CASE
AUTH/2159/8/08 Bristol-Myers Squibb Pharmaceuticals

AUTH/2159/8/08 and AUTH/2166/9/08: Anonymous v Bristol-Myers Squibb and Otsuka (alleged inappropriate hospitality) – No breach

Anonymous complainants alleged inappropriate hospitality at a psychiatrists’ meeting sponsored by Bristol-Myers Squibb and Otsuka. The Panel found the meeting’s purpose was…

2008
CASE
AUTH/2143/7/08 Syner-Med

Syner-Med detail aid ruled misleading on Ferinject dosing particulars (AUTH/2143/7/08)

A nurse alleged misleading claims about Ferinject dosing and safety at a Syner-Med exhibition stand and in a detail aid. The Panel…

2008
CASE
Bayer

Bayer Schering Pharma: Multiple sclerosis corporate advert in The Economist ruled to promote a prescription-only medicine to the public

An anaesthetist complained that a Bayer Schering Pharma advert in The Economist promoted a prescription-only MS medicine to the public and raised…

2009
CASE
AUTH/2208/2/09 Gilead Sciences ⭐ Case of the Week

AUTH/2208/2/09: Health professional v Gilead Sciences – unsolicited email about fellowship programme (no breach)

A health professional received an unsolicited email about Gilead’s UK and Ireland Fellowship Programme and queried how his private address was obtained…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training